U
Unimark Remedies
Healthcare company, developing affordable generic medicines in various therapeutic segments
About Unimark Remedies
In 1982, Unimark Remedies was founded, starting its journey as a marketing company. The playbook shifted in 1995 when the company integrated backwards into manufacturing Active Pharmaceutical Ingredients (APIs), the core components of medicines. This move set the stage for growth, and by 1997, Unimark acquired an antibiotic facility in Bavla, India. The company focused on developing and manufacturing generic drugs across therapeutic areas like respiratory and cardiovascular, aiming to be a global, integrated life sciences player. The mid-2000s marked a period of significant milestones, with its manufacturing plants in Vapi and Bavla receiving US FDA approval in 2006 and 2007, respectively. This opened the door for international expansion. In 2007, Citi Venture Capital invested Rs 113 crore for a 27% stake, valuing the company at Rs 380 crore. Another strategic investment came in 2011 from Hikma Pharmaceuticals, which acquired a minority stake for $33.3 million to gain access to Unimark's API manufacturing capabilities. However, the company's trajectory shifted. In 2018, after defaulting on a major loan, Unimark Remedies was admitted for corporate insolvency. The story took its final turn in April 2023, when a bankruptcy court approved an acquisition plan from a consortium including Intas Pharmaceuticals and Shamrock Pharmachemi for about Rs 250 crore. Today, Unimark Remedies is 100% owned and managed by the Shamrock Pharmagroup, closing one chapter and beginning another under new ownership.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Apr 2011 | $33M | $133M | Hikma Pharmaceuticals | — |
Growth signals
Latest recorded traffic for Unimark Remedies is 10K monthly website visits, up 2602.7% over the last three months. Unimark Remedies's team grew 3.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Unimark Remedies in the Mumbai ecosystem
The Unimark Remedies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Hikma Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Unimark Remedies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Unimark Remedies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







